TesoRx Product Pipeline

TSX-049 is a novel, oral formulation of Testosterone (T) containing Testosterone Undecanoate (TU) that is designed to help restore normal T levels in males with hypogonadism. We believe our product would be successful in treating age related hypogonadism. The successful completion of a confirmative study in canines was designed to predict the pharmacokinetic profile of TSX-049 for the oral treatment of hypogonadism.

The results of the study confirmed that the optimized TSX-049 formulation has enhanced bioavailability and a dose response sufficient to overcome negative feedback of gonadal testosterone production. TesoRx will be advancing TSX-049 into Phase 1-2a human clinical trials and anticipates a potential U.S. Food and Drug Administration approval in early 2027.

LiPax is the very first precision targeted, locally delivered taxane technology platform. Its growing pipeline targets areas of great unmet need in Bladder Cancer, Malignant Pleural Effusion (MPE), Upper Tract Urothelial Carcinoma, Stage II/III Ovarian Cancer, and Intraperitoneal Carcinoma.